(Another) New AI Biopharma Company | Science | AAAS

News has come of the start of a new AI-centric biopharma company, Xaira. They say that have over a billion dollars in funding lined up from ARCH Venture Partners and a number of other investors, and there are a number of marquee names involved (such as David Baker and his protein-design group at Washington). Interestingly, the head of the new company is Marc Tessier-Lavigne, whose name may well resonate. He was at one time Genentech's CSO, and has also been president of Rockefeller University and then president of Stanford. And that's the position that he stepped down from last July amid the publicity around doctored images that were present in a number of his scientific publications. I'm sure that he hates deeply the way that this comes up every time his name is mentioned, but there's no way for it not to - particularly given his extremely vehement denials that any such image doctoring had ever taken place. Stanford's eventual report on the affair concluded that Tessier-Lavigne did no

saved by

• Sri Nandan Gondi